AT
The startup develops small molecule drugs that target nuclear receptors and master transcription factors to regulate cellular metabolism. This approach aims to enhance patient health by providing effective treatments for metabolic disorders.
Updated 2 months ago
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops small molecule drugs that target nuclear receptors and master transcription factors to regulate cellular metabolism. This approach aims to enhance patient health by providing effective treatments for metabolic disorders.